If you have joint pain and have started researching regenerative options, you have almost certainly encountered claims that seem too good to be true: stem cell injections that “regrow cartilage,” “reverse arthritis,” or “eliminate the need for knee replacement.” Some of those claims come from real science. Many do not. The gap between what clinical trials have actually reported and what clinics are selling is wide, and navigating it requires a clear-eyed look at the evidence on its own terms.
This article covers the orthobiologics research landscape, specifically what registered clinical trials have reported about adipose-derived stem cells (ADSCs) in knee, hip, and shoulder applications. It explains the outcome measures those trials use, presents the data honestly including its limitations, and gives you the tools to evaluate claims critically rather than rely on marketing.
TLDR: Adipose-derived stem cells are among the most actively studied cell populations in orthobiologics, particularly for knee osteoarthritis. A Phase III randomized controlled trial of 261 patients and a meta-analysis of 377 patients across nine trials have both reported statistically significant improvements in pain and function measures. These findings are investigational. No ADSC-based orthopedic therapy is FDA-approved in the United States. Shoulder research is early-phase. Hip data has significant gaps. Read on for the full picture.
Important Disclaimer: No ADSC-based orthopedic therapy is currently FDA-approved in the United States. Save My Fat does not provide FDA-approved treatments or cures for any disease or medical condition. Adipose tissue banking is a preservation service for potential future opportunities, not a therapeutic product. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. All content on this site is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Patients must consult their own licensed healthcare professionals regarding all medical decisions. Outcomes of any regenerative medicine research or future therapies are highly individual and cannot be predicted or guaranteed.
Joint conditions are one of the most common reasons patients start investigating regenerative medicine. Osteoarthritis affects an estimated 32.5 million adults in the United States, and for many of them, the choice between living with pain and undergoing joint replacement surgery is an uncomfortable one. That gap has fueled enormous research interest in whether biologically derived products, particularly those derived from a patient’s own tissue, can modulate joint environments and slow progression.
ADSCs sit at the center of that research for several reasons: they are abundant, minimally invasive to collect, autologous by default, and carry a paracrine secretome that preclinical research has consistently linked to anti-inflammatory and anti-catabolic effects in cartilage tissue. If you want the full background on what ADSCs are and how they communicate with surrounding tissue, the patient’s guide to adipose-derived stem cells and the guide to paracrine signaling cover both in plain language.
This article assumes that basic familiarity and focuses specifically on what the clinical trial record shows for musculoskeletal applications.
What Is Orthobiologics and Where Do ADSCs Fit?
Orthobiologics is the field of musculoskeletal medicine that studies biologically derived substances for the potential repair or modulation of joint, bone, tendon, and cartilage tissue. It is a broad category. At the less complex end sits platelet-rich plasma (PRP), derived from a patient’s own blood and concentrated platelets. Further along the spectrum sits bone marrow aspirate concentrate (BMAC), derived from bone marrow and containing a mixture of growth factors and progenitor cells. ADSCs represent one of the most cell-rich and mechanistically complex options in the field.
What makes ADSCs particularly interesting in orthobiologics research is a combination of factors that the comparison of bone marrow and adipose-derived stem cells covers in detail. Adipose tissue yields 500 to 1,000 times more mesenchymal stem cells per volume than bone marrow. ADSCs demonstrate chondrogenic differentiation potential, meaning they can produce the proteins (SOX9, collagen type II, aggrecan) associated with cartilage tissue in lab and joint environments. Their paracrine secretome, including VEGF, TGF-beta, IGF-1, and bFGF, has been observed in preclinical models to suppress cartilage-degrading enzymes (MMP-3, MMP-13, ADAMTS5) and reduce pro-inflammatory cytokines like TNF-alpha and IL-1 in the synovial environment. They also survive longer in joint environments compared to perinatal MSCs, which matters in a research context where the duration of paracrine activity affects what the study can measure.
No orthobiologic, including PRP, BMAC, or ADSCs, is currently FDA-approved for any joint condition in the United States.
| Orthobiologic | Source | Primary Mechanism | Strongest Current Evidence | FDA Status (US) |
|---|---|---|---|---|
| PRP (Platelet-Rich Plasma) | Patient’s blood (platelets) | Growth factor delivery (PDGF, TGF-beta, VEGF) | Tendinopathy, mild-to-moderate knee OA | Not approved for joint conditions |
| BMAC (Bone Marrow Aspirate Concentrate) | Iliac crest bone marrow | Mixed progenitor cells, growth factors | Early Phase I/II joint and bone studies | Not approved for joint conditions |
| ADSCs | Adipose (fat) tissue | Paracrine signaling, immunomodulation, chondrogenic potential | Phase III knee OA randomized controlled trials | Not approved for any joint condition |
Understanding What Trials Actually Measure
Before reviewing what specific trials have reported, it is worth pausing on the vocabulary. Trial results are reported in standardized outcome measures, and understanding what those measures mean is the first step toward evaluating them critically rather than accepting a clinic’s interpretation of them.
The guide to clinical trial phases explains what Phase I, II, and III designations mean and what each phase is designed to establish. The measures below are what trials use to track change in joint conditions specifically.
| Outcome Measure | What It Is | What Lower/Better Scores Mean |
|---|---|---|
| VAS (Visual Analog Scale) | Patient self-reports pain on a 0-10 scale | Lower = less pain reported |
| WOMAC (Western Ontario and McMaster Universities OA Index) | Standardized assessment of pain, stiffness, and physical function | Lower = better function, less pain/stiffness |
| MRI Cartilage Assessment | Imaging of cartilage thickness, defect progression, and structure | Reduced defect progression = structural improvement |
| Kellgren-Lawrence (KL) Grade | Radiographic classification of OA severity, Grade 0 (none) to Grade 4 (severe) | Lower grade = less severe OA; most ADSC trials target Grade 2-3 |
| Lysholm Score | Functional assessment used in knee and sports medicine contexts | Higher = better functional performance |
When a clinic tells you that patients “improved significantly,” the meaningful follow-up questions are: improved on which measure, by how much, compared to whom, and over what time period? Trials that use validated, standardized measures with placebo or active comparator controls are more informative than single-group observational studies.
What Knee Osteoarthritis Trials Have Reported
The most clinically mature ADSC orthobiologics research focuses on knee osteoarthritis. The volume of registered trials, the presence of randomized controlled designs, and the progression to Phase III make knee OA the application with the strongest available evidence base. That evidence must still be read carefully.
The Phase III Landmark Trial
The most rigorous published ADSC knee OA data comes from a Phase III, multicenter, randomized, double-blind, placebo-controlled trial of 261 patients with Kellgren-Lawrence Grade 3 knee osteoarthritis. The trial evaluated a single intra-articular injection of 100 million (1 x 10^8) autologous cultured ADSCs versus placebo. Results were published in the Journal of Orthopaedic Surgery and Research (PMID 37345256).
The trial reported the following at six-month follow-up:
- VAS pain scores showed significantly greater reduction in the ADSC group compared to the placebo group (p < 0.05)
- WOMAC function scores demonstrated significant improvement in the ADSC group (p < 0.05)
- MRI cartilage assessment showed reduced defect progression in the ADSC group
- Safety profile: no serious adverse events were reported; the treatment was well tolerated
| Study Element | Detail |
|---|---|
| Design | Phase III, multicenter, randomized, double-blind, placebo-controlled |
| Participants | 261 patients, Kellgren-Lawrence Grade 3 knee OA |
| Intervention | Single intra-articular injection of 1 x 10^8 autologous cultured ADSCs |
| Primary Endpoint | 6 months |
| Reported VAS Outcome | Significantly greater pain reduction vs. placebo (p < 0.05) |
| Reported WOMAC Outcome | Significant improvement in function scores (p < 0.05) |
| MRI Finding | Reduced cartilage defect progression in ADSC group |
| Safety | No serious adverse events; well tolerated |
| Publication | Journal of Orthopaedic Surgery and Research, PMID 37345256 |
Meta-Analysis Context
A meta-analysis published in Frontiers in Pharmacology synthesized results from 9 randomized controlled trials involving 377 patients with knee osteoarthritis (available at doi.org/10.3389/fphar.2022.854025). Across included trials, the analysis reported:
- VAS pain reduction: statistically significant at all time points (single injection: Z = 3.10, p = 0.0001; multiple injections: Z = 4.66, p < 0.00001)
- WOMAC improvement: significant for both single and multiple injection groups
- MRI cartilage improvement: Z = 8.14, p < 0.000001 (single injection); Z = 5.58, p < 0.00001 (multiple injections)
- Reported effects sustained through 12 to 24 months of follow-up across included studies
- No serious adverse events across included trials
A meta-analysis synthesizes results across studies, which increases statistical power but also incorporates the limitations of each individual study. Differences in patient populations, cell preparation methods, injection protocols, and follow-up periods across the 9 included trials mean these aggregate results should be interpreted with appropriate caution.
Combination Therapy Findings
One additional study examined the combination of high tibial osteotomy (HTO), a surgical procedure that realigns the knee, with ADSC injection in 46 patients. The study compared HTO alone against HTO combined with ADSC injection. Researchers reported that the combination group showed significantly better cartilage regeneration on MRI assessment, with findings including reduced inflammation, improved cartilage thickness, and a shift in OA grade distribution toward less severe grades. This is investigational; the combination approach is not an FDA-approved therapy.
All data described in this section are from investigational clinical trials. No ADSC-based therapy for knee osteoarthritis is currently FDA-approved in the United States. These findings represent what specific trials reported in controlled research settings and do not establish that this treatment is safe and effective for individual patient use.
Shoulder Research: Where Does the Evidence Stand?
Shoulder ADSC research is significantly less mature than knee OA research. The volume of completed trials, the phase of available data, and the size of study populations are all smaller. That is not a reason to dismiss shoulder research, but it is important context for anyone evaluating it.
The most relevant registered study is NCT02918136, a Phase I/II trial investigating ADSC injection in partial-thickness rotator cuff tears. Early reported findings from this study included a safe administration profile, potential for tissue modulation, reduced inflammation markers, and improved function scores. Phase I/II trials are designed primarily to establish safety and observe early signals, not to prove effectiveness at scale. Understanding what that means for how to interpret these findings is covered in the guide to clinical trial phases.
One additional case in the published literature involves treatment of acromioclavicular (AC) joint osteoarthritis in a 43-year-old patient who received two injections (10 million cells initially, followed by 8 million cells at 5 months). Reported findings included NPRS pain scores moving from 5 out of 10 to 0 out of 10 at 18 months, QuickDASH functional scores showing consistent improvement, and MRI at 12 months showing complete resolution of synovitis, subchondral edema, and cyst reduction, with no adverse events. This must be understood for what it is: a single case report, which is the lowest level of clinical evidence. Case reports are interesting and hypothesis-generating, but they are not a basis for conclusions about effectiveness.
No ADSC-based therapy for any shoulder condition is FDA-approved. Shoulder research is at an early stage where the priority is establishing safety profiles before larger efficacy-focused trials can be designed.
Hip Research: An Honest Assessment
The honest picture for hip-specific ADSC research is that it is less mature than knee data by a significant margin. Several Phase I and Phase II trials investigating ADSC applications in hip osteoarthritis have been registered on ClinicalTrials.gov, but no Phase III hip-specific ADSC trial has been published with the same volume of data as the knee OA research described above.
This gap exists for a practical reason: knee osteoarthritis is the most common large-joint OA target in the United States, which drives more research funding, more trial registrations, and more published results. Hip OA is the next most common, but the trial landscape simply has not reached the same maturity.
What this means for patients with hip conditions is a realistic expectation of continued early-phase research, no approved therapies, and monitoring of the ClinicalTrials.gov registry for new enrolling studies. For context on an adjacent area of research that applies to multiple joint types, the guide to microfragmented adipose tissue (MFAT) covers a different approach to adipose-derived orthobiologics that has generated its own early-phase evidence base. For the broader landscape of where adipose-derived research is heading, the emerging research overview provides additional context.
ADSCs vs. PRP: Honest Comparison
The most common question patients ask when they encounter ADSC orthobiologics research is how it compares to platelet-rich plasma (PRP), the orthobiologic they are most likely to have been offered at a clinic. The honest answer requires distinguishing between what the science shows and what is being sold.
PRP is derived from a patient’s own blood, which is drawn, processed in a centrifuge to concentrate platelets, and then injected at the target site. It delivers a concentrated payload of growth factors (PDGF, TGF-beta, VEGF) and has been studied longer and across more completed human trials than ADSCs. PRP has its strongest evidence in tendinopathies and mild-to-moderate knee OA. It does not contain stem cells, and the consistency of its composition varies considerably depending on the preparation method.
ADSCs are being studied for potentially longer-duration effects, in part because living cells can produce paracrine factors over a sustained period rather than delivering a single bolus of growth factors the way PRP does. The Phase III and meta-analysis data described above represent a stronger evidentiary foundation for knee OA than most single PRP trials can claim individually. However, the total volume of completed ADSC trials is still smaller than the PRP literature.
| Feature | PRP | ADSCs |
|---|---|---|
| Source | Patient’s blood (platelets) | Patient’s fat tissue (stem cells) |
| Primary Mechanism | Growth factor delivery | Paracrine signaling, immunomodulation, chondrogenic potential |
| Evidence Base | Stronger in tendinopathy, mild-to-moderate knee OA | Phase III data for knee OA; early-phase shoulder/hip |
| FDA Status (US) | Not approved for joint conditions | Not approved for any joint condition |
| Consistency | Variable by preparation method | Variable by cell culture and preparation |
| Typical Context | Clinic-based, often out-of-pocket | Both clinical trials and (unregulated) clinic offerings |
One important warning: some clinics market “stem cell injections” that are not what they claim. The product being injected may be PRP labeled as stem cells, amniotic or umbilical cord tissue marketed as stem cells, or other preparations that do not meet any scientific definition of ADSC therapy. The guide to spotting fake stem cell clinics provides a detailed breakdown of how to identify these red flags before committing to any procedure.
What “No FDA Approval” Means If You Have Joint Pain Today
For patients experiencing joint pain who are researching regenerative options, the regulatory reality is specific and practical. As of April 2026, no ADSC-based orthopedic product has completed the FDA’s Biologics License Application (BLA) process for any musculoskeletal indication in the United States. That means no ADSC joint therapy has the FDA’s determination of safety and effectiveness behind it.
Some procedures are performed at US clinics under various regulatory interpretations, and some physicians point to same-day surgical exemptions or other frameworks to offer these services. But these procedures are subject to FDA enforcement, and patients paying out-of-pocket for unapproved procedures have no FDA-backed assurance that the product is safe, consistently prepared, or effective. The FDA consumer alert on unapproved regenerative medicine products addresses this directly and documents cases of patient harm from unapproved cellular products.
The pathways that currently exist for accessing investigational ADSC therapies legitimately are clinical trial enrollment (covered in detail in the guide to clinical trial phases) and Expanded Access programs for patients who meet specific eligibility criteria and have exhausted other options (covered in the expanded access programs guide). The guide to understanding FDA regulations for adipose tissue explains why the regulatory pathway matters and what patients should ask before agreeing to any procedure.
Red flags that suggest a clinic is operating outside the bounds of legitimate research include: no ClinicalTrials.gov registration number, no IRB oversight, charges to patients for the investigational product itself, claims of FDA approval, and guarantees of results. Legitimate trials do not promise outcomes.
How Tissue Banking Relates to the Orthobiologics Research Landscape
For patients with joint conditions, the connection between the orthobiologics research described in this article and adipose tissue banking is specific and should be stated honestly.
The orthobiologics trial data described here, including the Phase III knee OA results, used autologous tissue: ADSCs derived from the same patient’s own fat, harvested for that study and processed for that specific intervention. If future FDA-approved ADSC orthopedic therapies or clinical trials are designed to use a patient’s previously banked autologous tissue as starting material, having preserved that tissue at an earlier biological age could be relevant to eligibility or to the quality of the cells available. This connection is scientifically grounded but speculative about future trial designs: no currently approved or actively recruiting trial requires or uses consumer-banked adipose tissue as the source.
What banking does concretely is preserve the option. Cells stored now are preserved at their current biological state. If FDA-regulated pathways open that require autologous adipose tissue, the question of whether a patient has viable, well-characterized banked tissue becomes relevant. The decision is about preserving optionality in an uncertain future, not about securing access to any specific therapy.
Save My Fat helps individuals preserve their own adipose tissue through validated cryopreservation protocols for potential future opportunities that may arise as regenerative medicine science and FDA regulations evolve. Banked tissue does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. Any future use depends on the regulatory status of products or procedures at that time, the patient’s clinical situation, physician guidance, and availability of FDA-regulated pathways.
To understand the full banking process, see the complete guide to adipose tissue banking. For information specific to joint and orthopedic research, the joint and orthopedic research section of the Save My Fat site covers this research area in more depth.
Frequently Asked Questions
What is orthobiologics and why are researchers studying ADSCs in this field?
Orthobiologics is the branch of musculoskeletal medicine that studies biologically derived substances for potential repair or modulation of joint, bone, tendon, and cartilage tissue. Researchers study ADSCs in this field because adipose tissue provides an unusually abundant source of mesenchymal stem cells, those cells demonstrate both differentiation potential relevant to cartilage and an anti-inflammatory paracrine secretome, and they are autologous, meaning they come from the patient’s own body and carry no immune rejection risk. The combination of abundance, paracrine activity, and autologous origin makes them an attractive research target for conditions like osteoarthritis where inflammation and cartilage degradation are central problems.
What outcome measures do orthobiologics trials use?
The most common measures in joint OA trials are the VAS (Visual Analog Scale), a 0-10 patient-reported pain scale; the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index), a standardized assessment of pain, stiffness, and physical function; and MRI cartilage assessment, which tracks structural changes in cartilage over time. Kellgren-Lawrence grading is used to classify OA severity radiographically. Understanding these measures helps patients evaluate whether reported improvements are clinically meaningful rather than just statistically significant.
What have Phase II and Phase III knee osteoarthritis ADSC trials actually reported?
A Phase III randomized, double-blind, placebo-controlled trial of 261 patients reported significantly greater VAS pain reduction and WOMAC function improvement in the ADSC group versus placebo, with reduced cartilage defect progression on MRI and no serious adverse events. A meta-analysis of 9 randomized controlled trials involving 377 patients reported statistically significant improvements in VAS, WOMAC, and MRI cartilage measures at all time points, with effects sustained through 12 to 24 months. These are research findings from controlled trials. No ADSC-based therapy for knee osteoarthritis is FDA-approved.
How does ADSC research compare to PRP research in orthobiologics?
PRP has more published human trial data overall, with its strongest evidence in tendinopathy and mild-to-moderate OA. ADSCs are being studied for potentially longer-duration effects because living cells continue to produce paracrine factors over time, unlike PRP which delivers a one-time bolus of growth factors. The Phase III ADSC data for knee OA represents a rigorous evidentiary level that most individual PRP trials have not yet reached for that specific indication. Neither is FDA-approved for joint conditions in the United States.
What shoulder research has been done with ADSCs?
The most notable registered study is NCT02918136, a Phase I/II trial in partial-thickness rotator cuff tears that reported a safe administration profile, potential tissue modulation, and improved function scores. A single case report involving AC joint OA showed notable improvements at 18 months, including MRI resolution of synovitis and subchondral edema. Shoulder ADSC research is early-phase. The evidence base is significantly less mature than knee OA research, and no ADSC-based shoulder therapy is FDA-approved.
What early hip research exists?
Several Phase I and Phase II ADSC hip trials have been registered on ClinicalTrials.gov, but no Phase III hip-specific ADSC trial has produced the volume of published data that exists for knee OA. The hip evidence gap is real and worth acknowledging honestly. Patients interested in hip applications should monitor trial registrations at ClinicalTrials.gov and discuss enrollment eligibility with their physician.
What are the limitations of the current evidence?
The current ADSC orthobiologics evidence has meaningful limitations. Most trials are relatively small, short-term, and conducted at specialized research centers under controlled conditions that may not reflect routine clinical practice. Variation in cell preparation methods, injection protocols, and patient populations makes comparisons across trials difficult. The Phase III knee data and meta-analysis are encouraging, but they have not yet resulted in FDA approval, which requires a full BLA review. No randomized trial can guarantee individual results.
What does “no FDA approval” mean practically for a patient with joint pain today?
It means no ADSC joint therapy has passed the FDA’s formal determination of safety and effectiveness for any musculoskeletal indication. Clinics offering ADSC joint injections outside of registered trials are providing unapproved procedures. Patients paying for these services have no FDA-backed assurance of product quality, safety, or efficacy. The legitimate access pathways are clinical trial enrollment and Expanded Access programs. Patients should consult their orthopedic physician about whether any currently enrolling trials are appropriate for their specific situation.
What should patients watch for when clinics market stem cell joint injections?
Key red flags include: no ClinicalTrials.gov registration number for the procedure being offered, claims of FDA approval, guarantees of specific outcomes, charges for the investigational product itself, no mention of IRB oversight, and use of “stem cells” to describe products that are actually PRP, amniotic tissue, or other preparations. The guide to identifying fake stem cell clinics provides a comprehensive checklist. The FDA consumer alert documents serious adverse events from unapproved products.
How does tissue banking connect to the orthobiologics research landscape?
Banking preserves autologous adipose tissue at its current biological state for potential future use in FDA-regulated pathways. If future approved ADSC orthopedic therapies or clinical trials require autologous cells, banked tissue may be relevant to a patient’s eligibility or to the biological quality of cells available. This connection is speculative about future trial and product designs. Banking does not guarantee access to any existing or future trial, and no currently enrolling trial uses consumer-banked tissue as its source material. The decision is about preserving optionality, not securing a treatment.
Key Takeaways
- Orthobiologics is not monolithic. PRP, BMAC, and ADSCs are distinct approaches with different mechanisms, evidence bases, and regulatory statuses. None is FDA-approved for joint conditions in the United States.
- The Phase III knee OA data is the most rigorous in the field. A 261-patient randomized controlled trial and a meta-analysis of 377 patients across 9 trials both reported significant improvements in VAS, WOMAC, and MRI measures. These are investigational findings, not approved treatments.
- Shoulder research is early-phase. Phase I/II data and a single case report exist. Safety has been a primary focus. Efficacy at scale has not been established.
- Hip data has a real gap. Phase I/II trials are registered, but the volume and maturity of hip-specific data is significantly behind knee OA research.
- PRP and ADSCs are different things. Clinics that conflate them or misrepresent one as the other are a red flag. Understand what is being offered before agreeing to any procedure.
- Outcome measures matter. VAS, WOMAC, and MRI cartilage assessment are validated, standardized tools. Claims not anchored to these measures deserve skepticism.
- FDA approval requires a BLA, not just trial results. Positive Phase III data is necessary but not sufficient. No ADSC orthopedic product has completed this process in the United States.
- Banking preserves optionality. For patients monitoring orthobiologics research, preserving autologous tissue now keeps options open if future FDA-regulated pathways emerge that require it.
Learn More About Adipose Tissue Banking
The orthobiologics research landscape is moving steadily from early-phase investigation toward larger, more rigorous trials. For patients with joint conditions who are following that research closely, tissue banking is a way to stay positioned for what comes next without waiting to see which therapies ultimately reach FDA approval.
Save My Fat helps individuals preserve their own adipose tissue through validated cryopreservation protocols for potential future opportunities that may arise as regenerative medicine science and FDA regulations evolve. Banking does not guarantee eligibility, access, or clinical benefit from any future therapy. Save My Fat does not provide FDA-approved treatments or cures.
To learn more, visit savemyfat.com. For patient-specific information, see the patients section. If you are a provider interested in offering tissue banking to your patients, visit the providers section.
This article is for educational purposes only and does not constitute medical advice. Please consult your licensed healthcare provider regarding all medical decisions.
Last Updated: April 3, 2026
